Dr Alan Lewis Joins Biotica Board
Biotica Technology Ltd announced the appointment of Dr Alan Lewis as a Non-Executive Director with immediate effect.
Dr Alan Lewis is the President & CEO of the Juvenile Diabetes Research Foundation. Prior to joining the JDRF in January 2009, Dr. Lewis was CEO of the San Diego biotech company, Novocell. Previously he served as President of the Signal Division of Celgene, where he managed a fully integrated target and drug discovery effort consisting of 150 staff, including scientists, project planning, intellectual property, and business development. Dr. Lewis was President and CEO of Signal Pharmaceuticals until its acquisition by Celgene. He also was Vice President of Research at Wyeth Laboratories.
Born in Wales, Dr. Lewis has degrees in physiology, biochemistry and pharmacology from Southampton University and the University of Wales in Cardiff. He did postgraduate work at the University of Guelph, Ontario, and Yale University. He has published over 120 full manuscripts, and written and edited seven books and some 100 abstracts.
At the same time, Biotica announces that Marc Schneidman, Managing Director at Aquilo Partners (San Francisco), has been elected Chairman, and that Dr. Mike Hayes and Dr. Barrie Ward have resigned as Non-Executive Directors. Dr. Hayes had been a Director since 2000 and Chairman since 2003, and Dr. Ward a Director since 2004. Both have played an important role in guiding the company to its current position of strength.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
